← Back to patent-cliff list
Mometasone eluting resorbable scaffold (Lyra Therapeutics)
Tier C — Watch / tradeMometasone eluting resorbable scaffold (Lyra Therapeutics)
Lyra Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：GR
Indications (approved)：Sinusitis
Regional status
US
Phase III
2022-01-27
EU
Phase III
2022-01-27
China
IND filed
2023-02-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Mometasone eluting resorbable scaffold (Lyra Therapeutics)?
Approved indications include: Sinusitis.
When does the Mometasone eluting resorbable scaffold (Lyra Therapeutics) patent expire?
No public expiry year is available for Mometasone eluting resorbable scaffold (Lyra Therapeutics) yet; this page updates once verified.
How do I get a quote for Mometasone eluting resorbable scaffold (Lyra Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21